Genetic result; CDKN2A mutation: does it mean anything for my approach to PCa treatment?

[45RPM]

Genetic testing has revealed CDKN2A mutation which leaves me a higher risk for skin cancer and pancreatic cancer, wasn't too surprised as my Dad had melanoma.

Report says: "it is unclear if this CDKN2A mutation is related to the prostate cancer of this patient. Follow-up IHC analysis of the p16 protein on a tumor tissue sample may help better determine if this variant has a role in the prostate cancer", and it also says: " The germline CDKN2A mutation was also detected in the tumor sample tested, but without loss of heterozygosity or a somatic second hit in the tumor tissue." Anyone got any insights on these?

Wonder as well if this means i should look a radiation vs surgery any differently now - so if i expect to have to deal with more radiation later, does it push me more towards surgery now.

[Tall_Allen]

Why do you think it has any impact on your treatment decision? I don't see any connection.

[45RPM in reply to Tall_Allen]

I also don't know of a connection but that is why I am asking the experts here to make sure I don't miss anything to consider. Like if there is some connection that might imply my PCa is more aggressive, or should go surgery on PCa to avoid additional exposure to radiation later if I need to treat future cancers

[Tall_Allen in reply to 45RPM]

Radiation in different places is OK. The key parameters are Gleason score, PSA, and stage.